First Time Loading...

United Therapeutics Corp
NASDAQ:UTHR

Watchlist Manager
United Therapeutics Corp Logo
United Therapeutics Corp
NASDAQ:UTHR
Watchlist
Price: 238.485 USD 1.98% Market Closed
Updated: Apr 29, 2024

United Therapeutics Corp
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

United Therapeutics Corp
Operating Income Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
United Therapeutics Corp
NASDAQ:UTHR
Operating Income
$1.2B
CAGR 3-Years
26%
CAGR 5-Years
8%
CAGR 10-Years
15%
Abbvie Inc
NYSE:ABBV
Operating Income
$16.6B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$9.3B
CAGR 3-Years
32%
CAGR 5-Years
2%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Operating Income
$8.2B
CAGR 3-Years
-4%
CAGR 5-Years
-5%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$3.8B
CAGR 3-Years
10%
CAGR 5-Years
42%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4.2B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
19%

See Also

What is United Therapeutics Corp's Operating Income?
Operating Income
1.2B USD

Based on the financial report for Dec 31, 2023, United Therapeutics Corp's Operating Income amounts to 1.2B USD.

What is United Therapeutics Corp's Operating Income growth rate?
Operating Income CAGR 10Y
15%

Over the last year, the Operating Income growth was 20%. The average annual Operating Income growth rates for United Therapeutics Corp have been 26% over the past three years , 8% over the past five years , and 15% over the past ten years .